The Technology Allocation Trap

In this episode of Bench to Boardroom, we explore why not all technology investments in life sciences are created equal — and why following the hype around AI and digital transformation may generate far weaker returns than many executives expect. The discussion examines where emerging technologies can create meaningful strategic advantage across clinical development, commercialization, market access, launch sequencing, regulatory intelligence, manufacturing, and supply chain operations, while also highlighting where excessive or poorly targeted tech investment may lead to diminishing returns. Ultimately, the episode argues that the leaders who win with technology are not those investing the most, but those investing most intelligently — aligning technology with the realities of science, operations, and commercial execution.